Press

Field Trip Health & Wellness Ltd. Announces Launch of Online Therapy

Jan 12 • 3 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW), a global leader in the delivery of psychedelic therapies, today launched Field Trip Online Therapy, a unique approach to psychotherapy that leverages contemporary talk therapy, integrative wellness tools and insights derived from being one of the largest global providers of psychedelic-assisted therapies. The new offering marks a…

Revive Therapeutics Ltd. Closes $4.3 Million Offering

Jan 12 • 2 min read

REVIVE THERAPEUTICS LTD. (CSE: RVV OTCQB: RVVTF | FRANKFURT:31R) is pleased to announce that it has completed the closing of its previously announced private placement by issuing a total of 28,676,064 units, at a price of $0.15 per Unit, for gross proceeds of $4,301,409. Each Unit is comprised of one common share in the capital…

Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US

Jan 10 • 4 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X), is proud to announce it has signed a Letter of Intent entering into a partnership with Braxia Scientific Corp. (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, to launch Clinical…

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Jan 10 • 2 min read

Clearmind Medicine Inc. (Nasdaq: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate…

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Jan 10 • 2 min read

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF) examining psilocybin’s effect on inflammatory activity in humans. The clinical study evaluates three populations of patients suffering from Parkinson’s disease, bipolar…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435